Legend Biotech (LEGN) Preferred Stock Liabilities (2020 - 2021)
Legend Biotech (LEGN) posted Preferred Stock Liabilities of $80.0 million for Q3 2021, up 200.0% on a QoQ basis from -$80.0 million in Q4 2020, and up 200.0% year-over-year from $26.7 million in Q3 2020.
Legend Biotech (LEGN) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Legend Biotech's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $80.0 million for Q3 2021.
- Quarterly Preferred Stock Liabilities rose 200.0% year-over-year to $80.0 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $80.0 million (up 200.0% YoY) and the FY2020 annual result came in at $80.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $80.0 million for Q3 2021 at Legend Biotech, up from -$80.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $80.0 million in Q3 2021 and bottomed at -$80.0 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Legend Biotech | 8.26 Bn | 7.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 79.98 Mn |
| Dec 31, 2020 | -79.98 Mn |
| Sep 30, 2020 | -79.98 Mn |
| Jun 30, 2020 | -79.98 Mn |